Tearlab Corporation v. I-MED Pharma Inc., 2019 FCA 179

CourtFederal Court of Appeal (Canada)
Case DateJune 13, 2019
JurisdictionCanada (Federal)
Citations2019 FCA 179
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
33 practice notes
  • Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
    • Canada
    • Federal Court (Canada)
    • April 7, 2022
    ...limitation in the claims is “a self inflicted wound” (Free World Trust, para 51, cited recently in Tearlab Corporation v I-MED Pharma Inc, 2019 FCA 179 [Tearlab] at para 32 and, in particular on the notion of essential vs. non-essential claims, Easton Sports Canada Inc. v Bauer Hockey Corp.......
  • Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...as it then read, promotes adherence to the language of the claims. [164] In a more recent decision, the FCA in Tearlab v I-MED Pharma Inc, 2019 FCA 179 at para 47 [Tearlab FCA] approved the trial judge’s construction and his adherence to the words of the claims. The trial judge refused to a......
  • Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...as it then read, promotes adherence to the language of the claims. [109] In a more recent decision, the FCA in Tearlab v I-MED Pharma Inc, 2019 FCA 179 at para 47 [Tearlab FCA] approved the trial judge’s construction and his adherence to the words of the claims. The trial judge refused to a......
  • WESTERN OILFIELD EQUIPMENT RENTALS LTD. and FP MARANGONI INC. v. M-I L.L.C., 2021 FCA 24
    • Canada
    • Court of Appeal (Canada)
    • February 9, 2021
    ...such evidence by the trial judge is reviewed on a standard of palpable and overriding error: see Tearlab Corporation v. I-MED Pharma Inc., 2019 FCA 179, 166 C.P.R. (4th) 367 at para. 29. Accordingly, even if I would not have reached the same conclusions on the expert evidence heard by the F......
  • Request a trial to view additional results
35 cases
  • Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
    • Canada
    • Federal Court (Canada)
    • April 7, 2022
    ...limitation in the claims is “a self inflicted wound” (Free World Trust, para 51, cited recently in Tearlab Corporation v I-MED Pharma Inc, 2019 FCA 179 [Tearlab] at para 32 and, in particular on the notion of essential vs. non-essential claims, Easton Sports Canada Inc. v Bauer Hockey Corp.......
  • Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...as it then read, promotes adherence to the language of the claims. [164] In a more recent decision, the FCA in Tearlab v I-MED Pharma Inc, 2019 FCA 179 at para 47 [Tearlab FCA] approved the trial judge’s construction and his adherence to the words of the claims. The trial judge refused to a......
  • Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...as it then read, promotes adherence to the language of the claims. [109] In a more recent decision, the FCA in Tearlab v I-MED Pharma Inc, 2019 FCA 179 at para 47 [Tearlab FCA] approved the trial judge’s construction and his adherence to the words of the claims. The trial judge refused to a......
  • WESTERN OILFIELD EQUIPMENT RENTALS LTD. and FP MARANGONI INC. v. M-I L.L.C., 2021 FCA 24
    • Canada
    • Court of Appeal (Canada)
    • February 9, 2021
    ...such evidence by the trial judge is reviewed on a standard of palpable and overriding error: see Tearlab Corporation v. I-MED Pharma Inc., 2019 FCA 179, 166 C.P.R. (4th) 367 at para. 29. Accordingly, even if I would not have reached the same conclusions on the expert evidence heard by the F......
  • Request a trial to view additional results
2 firm's commentaries
  • 2019 Life Sciences Year In Review
    • Canada
    • Mondaq Canada
    • March 6, 2020
    ...that can impact the scope of the claims, and potentially lead to invalidity. The patent at issue in Tearlab Corporation v I-MED Pharma, 2019 FCA 179 ("Tearlab"), related to an invention used to measure the osmolarity of bodily fluids. The Federal Court found that the patent was invalid as b......
  • Beyond A 'Reasonably Diligent Search' In An Obviousness Attack
    • Canada
    • Mondaq Canada
    • November 6, 2019
    ...that this may not be the last word on the subject, as recently the Federal Court of Appeal in Tearlab Corporation v. I-MED Pharma Inc., 2019 FCA 179, appeared to accept that the reasonably diligent search test was The "Reasonably Diligent Search" Test The impeachment proceedings against the......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT